Low-density lipoprotein
Low-density lipoprotein (LDL) is one of the five major groups of
Overview
Lipoproteins transfer
The common clinical interpretation of blood lipid levels is that high LDL is associated with increased risk of
Biochemistry
Structure
Each native LDL particle enables emulsification, i.e. surrounding the fatty acids being carried, enabling these fats to move around the body within the water outside cells. Each particle contains a single
Physiology
LDL particles are formed when triglycerides are removed from VLDL by the lipoprotein lipase enzyme (LPL) and they become smaller and denser (i.e. fewer fat molecules with same protein transport shell), containing a higher proportion of cholesterol esters.[9][10]
Transport into the cell
When a cell requires additional cholesterol (beyond its current internal HMGCoA production pathway), it synthesizes the necessary LDL receptors as well as PCSK9, a proprotein convertase that marks the LDL receptor for degradation.[11] LDL receptors are inserted into the plasma membrane and diffuse freely until they associate with clathrin-coated pits. When LDL receptors bind LDL particles in the bloodstream, the clathrin-coated pits are endocytosed into the cell.
Vesicles containing LDL receptors bound to LDL are delivered to the
Role in the innate immune system
LDL interfere with the quorum sensing system that upregulates genes required for invasive Staphylococcus aureus infection. The mechanism of antagonism entails binding apolipoprotein B to a S. aureus autoinducer pheromone, preventing signaling through its receptor. Mice deficient in apolipoprotein B are more susceptible to invasive bacterial infection.[13]
LDL size patterns
LDL can be grouped based on its size: large low density LDL particles are described as pattern A, and small high density LDL particles are pattern B.[14] Pattern B has been associated by some with a higher risk for coronary heart disease.[15]: 1–10 This is thought to be because the smaller particles are more easily able to penetrate the endothelium of arterial walls. Pattern I, for intermediate, indicates that most LDL particles are very close in size to the normal gaps in the endothelium (26 nm). According to one study, sizes 19.0–20.5 nm were designated as pattern B and LDL sizes 20.6–22 nm were designated as pattern A.[16] Other studies have shown no such correlation at all.[17]
Some evidence suggests the correlation between Pattern B and coronary heart disease is stronger than the correspondence between the LDL number measured in the standard lipid profile test. Tests to measure these LDL subtype patterns have been more expensive and not widely available, so the common lipid profile test is used more often.[15]
There has also been noted a correspondence between higher triglyceride levels and higher levels of smaller, denser LDL particles and alternately lower triglyceride levels and higher levels of the larger, less dense ("buoyant") LDL.[18][19]
With continued research, decreasing cost, greater availability and wider acceptance of other lipoprotein subclass analysis assay methods, including
Oxidized LDL
Oxidized LDL is a general term for LDL particles with oxidatively modified structural components. As a result, from
Testing
Direct LDL measurements are also available and better reveal individual issues but are less often promoted or done due to slightly higher costs and being available from only a couple of laboratories in the United States. In 2008, the ADA and ACC recognized direct LDL particle measurement by NMR as superior for assessing individual risk of cardiovascular events.[26]
Estimation of LDL particles via cholesterol content
Chemical measures of lipid concentration have long been the most-used clinical measurement, not because they have the best correlation with individual outcome, but because these lab methods are less expensive and more widely available.
The lipid profile does not measure LDL particles. It only estimates them using the Friedewald equation[19][27] by subtracting the amount of cholesterol associated with other particles, such as
- where H is HDL cholesterol, L is LDL cholesterol, C is total cholesterol, T are triglycerides, and k is 0.20 if the quantities are measured in mg/dL and 0.45 if in mmol/L.
There are limitations to this method, most notably that samples must be obtained after a 12 to 14 h fast and that LDL-C cannot be calculated if plasma triglyceride is >4.52 mmol/L (400 mg/dL). Even at triglyceride levels 2.5 to 4.5 mmol/L, this formula is considered inaccurate.[28] If both total cholesterol and triglyceride levels are elevated then a modified formula, with quantities in mg/dL, may be used
This formula provides an approximation with fair accuracy for most people, assuming the blood was drawn after fasting for about 14 hours or longer, but does not reveal the actual LDL particle concentration because the percentage of fat molecules within the LDL particles which are cholesterol varies, as much as 8:1 variation. There are several formulas published addressing the inaccuracy in LDL-C estimation.[29][30][31] The inaccuracy is based on the assumption that VLDL-C (Very low density lipoprotein cholesterol) is always one-fifth of the triglyceride concentration. A new formulae published recently addresses this issue by using an adjustable factor [32] or by using a regression equation.[33] There are few studies which have compared the LDL-C values derived form this recently published formula and values obtained by direct enzymatic method.[34] Direct enzymatic method are found to be accurate and it has to be the test of choice in clinical situations. In the resource poor settings, the option of using the formula has to be considered.[34]
However, the concentration of LDL particles, and to a lesser extent their size, has a stronger and consistent correlation with individual clinical outcome than the amount of cholesterol within LDL particles, even if the LDL-C estimation is approximately correct. There is increasing evidence and recognition of the value of more targeted and accurate measurements of LDL particles. Specifically, LDL particle number (concentration), and to a lesser extent size, have shown slightly stronger correlations with atherosclerotic progression and cardiovascular events than obtained using chemical measures of the amount of cholesterol carried by the LDL particles.[35] It is possible that the LDL cholesterol concentration can be low, yet LDL particle number high and cardiovascular events rates are high. Correspondingly, it is possible that LDL cholesterol concentration can be relatively high, yet LDL particle number low and cardiovascular events are also low.
Normal ranges
In the US, the American Heart Association, NIH, and NCEP provide a set of guidelines for fasting LDL-Cholesterol levels, estimated or measured, and risk for heart disease. As of about 2005, these guidelines were:[36][37][38]
Level mg/dL | Level mmol/L | Interpretation |
---|---|---|
25 to <50 | <1.3 | Optimal LDL cholesterol, levels in healthy young children before onset of atherosclerotic plaque in heart artery walls |
<70 | <1.8 | Optimal LDL cholesterol, corresponding to lower rates of progression, promoted as a target option for those known to clearly have advanced symptomatic cardiovascular disease |
<100 | <2.6 | Optimal LDL cholesterol, corresponding to lower, but not zero, rates for symptomatic cardiovascular disease events |
100 to 129 | 2.6 to 3.3 | Near optimal LDL level, corresponding to higher rates for developing symptomatic cardiovascular disease events |
130 to 159 | 3.3 to 4.1 | Borderline high LDL level, corresponding to even higher rates for developing symptomatic cardiovascular disease events |
160 to 199 | 4.1 to 4.9 | High LDL level, corresponding to much higher rates for developing symptomatic cardiovascular disease events |
>200 | >4.9 | Very high LDL level, corresponding to highest increased rates of symptomatic cardiovascular disease events |
Over time, with more clinical research, these recommended levels keep being reduced because LDL reduction, including to abnormally low levels, was the most effective strategy for reducing cardiovascular death rates in one large
For instance, for people with known atherosclerosis diseases, the 2004 updated American Heart Association, NIH and NCEP recommendations are for LDL levels to be lowered to less than 70 mg/dL, unspecified how much lower. This low level of less than 70 mg/dL (higher than Tim Russert's value shortly prior to his heart attack) was recommended for primary prevention of 'very-high risk patients' and in secondary prevention as a 'reasonable further reduction'. Lack of evidence for such a recommendation is discussed in an article in the Annals of Internal Medicine.[41] Statin drugs involved in such clinical trials have numerous physiological effects beyond simply the reduction of LDL levels.
It has been estimated from the results of multiple human pharmacologic LDL lowering trials
A study was conducted measuring the effects of guideline changes on LDL cholesterol reporting and control for diabetes visits in the US from 1995 to 2004. It was found that although LDL cholesterol reporting and control for diabetes and coronary heart disease visits improved continuously between 1995 and 2004,[44][45] neither the 1998 ADA guidelines nor the 2001 ATP III guidelines increased LDL cholesterol control for diabetes relative to coronary heart disease.[46]
Direct measurement of LDL particle concentrations
There are several competing methods for measurement of lipoprotein particle concentrations and size. The evidence is that the NMR methodology (developed, automated & greatly reduced in costs while improving accuracy as pioneered by Jim Otvos and associates) results in a 22-25% reduction in cardiovascular events within one year,[47] contrary to the longstanding claims by many in the medical industry that the superiority over existing methods was weak, even by statements of some proponents.[48]
Since the later 1990s, because of the development of NMR measurements, it has been possible to clinically measure lipoprotein particles at lower cost [under $80 US (including shipping) & is decreasing; versus the previous costs of >$400 to >$5,000] and higher accuracy. There are two other assays for LDL particles, however, like LDL-C, most only estimate LDL particle concentrations.
Direct LDL particle measurement by NMR was mentioned by the ADA and ACC, in a 28 March 2008 joint consensus statement,[49] as having advantages for predicting individual risk of atherosclerosis disease events, but the statement noted that the test is less widely available, is more expensive [about $13.00 US (2015 without insurance coverage) from some labs which use the Vantera Analyzer[50]]. Debate continues that it is "...unclear whether LDL particle size measurements add value to measurement of LDL-particle concentration", though outcomes have always tracked LDL particle, not LDL-C, concentrations.
Using NMR, the total LDL particle concentrations, in nmol/L plasma, are typically subdivided by percentiles referenced to the 5,382 men and women, not on any lipid medications, who are participating in the MESA trial.[51]
Optimal ranges
The LDL particle concentrations are typically categorized by percentiles, <20%, 20–50%, 50th–80th%, 80th–95% and >95% groups of the people participating and being tracked in the MESA trial, a medical research study sponsored by the United States National Heart, Lung, and Blood Institute.
MESA Percentile | LDL particles nmol/L | Interpretation |
---|---|---|
0–20% | <1,000 | Those with lowest rate of cardiovascular disease events & low (optimal) LDL particle concentration |
20–50% | 1,000–1,299 | Those with moderate rate of cardiovascular disease events & moderate LDL particle concentration |
50–80% | 1,300–1,599 | Those with Borderline-High rate of cardiovascular disease events & higher LDL particle concentration |
89–95% | 1,600–2,000 | Those with High rate of cardiovascular disease events and even higher LDL particle concentration |
>95% | >2,000 | Those with very high rate of cardiovascular disease events and highest LDL particle concentration |
The lowest incidence of atherosclerotic events over time occurs within the <20% group, with increased rates for the higher groups. Multiple other measures, including particle sizes, small LDL particle concentrations, large total and HDL particle concentrations, along with estimations of insulin resistance pattern and standard cholesterol lipid measurements (for comparison of the plasma data with the estimation methods discussed above) are also routinely provided.
Lowering LDL-cholesterol
Markers indicating a need for LDL-C Reduction
(Per 2004 United States Government Minimum Guidelines[52][53]) | ||||
---|---|---|---|---|
If the patient's cardiac risk is... | then the patient should consider LDL-C reduction if the count in mg/dL is over... | and LDL-C reduction is indicated if the count in mg/dL is over... | ||
High, meaning a 20% or greater risk of heart attack within 10 years, or an extreme risk factor | 70[54] | 100[54] | ||
moderately high, meaning a 10-20% risk of heart attack within 10 years and more than 2 heart attack risk factors | 100[54] | 130[54] | ||
moderate, meaning a 10% risk of heart attack within 10 years and more than 2 heart attack risk factors | 130[54] | 160[54] | ||
low, meaning less than 10% risk of heart attack within 10 years and 1 or 0 heart attack risk factors | 160[54] | 190[54] |
The
LDL-C is not a measurement of actual LDL particles. LDL-C is only an estimate (not measured from the individual's blood sample) of how much cholesterol is being transported by all LDL particles, which is either a smaller concentration of large particles or a high concentration of small particles. LDL particles carry many fat molecules (typically 3,000 to 6,000 fat molecules per LDL particle); this includes cholesterol, triglycerides, phospholipids and others. Thus even if the hundreds to thousands of cholesterol molecules within an average LDL particle were measured, this does not reflect the other fat molecules or even the number of LDL particles.
Pharmaceutical
- PCSK9 inhibitors, in clinical trials, by several companies, are more effective for LDL reduction than the statins, including statins alone at high dose (though not necessarily the combination of statins plus ezetimibe).
- Statins reduce high levels of LDL particles by inhibiting the enzyme HMG-CoA reductase in cells, the rate-limiting step of cholesterol synthesis. To compensate for the decreased cholesterol availability, synthesis of LDL receptors (including hepatic) is increased, resulting in an increased clearance of LDL particles from the extracellular water, including of the blood.
- Ezetimibe reduces intestinal absorption of cholesterol, thus can reduce LDL particle concentrations when combined with statins.[55]
- Niacin (B3), lowers LDL by selectively inhibiting hepatic diacylglycerol acyltransferase 2, reducing triglyceride synthesis and VLDL secretion through a receptor HM74[56] and HM74A or GPR109A.[57]
- Several CETP inhibitors have been researched to improve HDL concentrations, but so far, despite dramatically increasing HDL-C, have not had a consistent track record in reducing atherosclerosis disease events. Some have increased mortality rates compared with placebo.
- Clofibrate is effective at lowering cholesterol levels, but has been associated with significantly increased cancer and stroke mortality, despite lowered cholesterol levels.[58] Other, more recently developed and tested fibrates, e.g. fenofibric acid[59] have had a better track record and are primarily promoted for lowering VLDL particles (triglycerides), not LDL particles, yet can help some in combination with other strategies.
- Some tocotrienols, especially delta- and gamma-tocotrienols, are being promoted as statin alternative non-prescription agents to treat high cholesterol, having been shown in vitro to have an effect. In particular, gamma-tocotrienol appears to be another HMG-CoA reductase inhibitor, and can reduce cholesterol production.[60] As with statins, this decrease in intra-hepatic (liver) LDL levels may induce hepatic LDL receptor up-regulation, also decreasing plasma LDL levels. As always, a key issue is how benefits and complications of such agents compare with statins—molecular tools that have been analyzed in large numbers of human research and clinical trials since the mid-1970s.
- Phytosterols are widely recognized as having a proven LDL cholesterol lowering efficacy'[61] A 2018 review found a dose-response relationship for phytosterols, with intakes of 1.5 to 3 g/day lowering LDL-C by 7.5% to 12%,[62] but reviews as of 2017 had found no data indicating that the consumption of phytosterols may reduce the risk of CVD.[63] Current supplemental guidelines for reducing LDL recommend doses of phytosterols in the 1.6-3.0 grams per day range (Health Canada, EFSA, ATP III, FDA) with a 2009 meta-analysis demonstrating an 8.8% reduction in LDL-cholesterol at a mean dose of 2.15 gram per day.[64]
Gene editing
In 2021, scientists demonstrated that
Lifestyle
LDL cholesterol can be lowered by through dietary intervention by limiting foods with saturated fat and avoiding foods with trans fat.[67] Saturated fats are found in meat products (including poultry), full-fat dairy, eggs, and refined tropical oils like coconut and palm.[68] Added trans fat (in the form of partially hydrogenated oils) has been banned in the USA since 2021.[69] However, trans fat can still be found in red meat and dairy products as it is produced in small amounts by ruminants such as sheep and cows.[70] LDL cholesterol can also be lowered by increasing consumption of soluble fiber and plant-based foods.[67]
Another lifestyle approach to reduce LDL cholesterol has been minimizing total body fat, in particular fat stored inside the abdominal cavity (visceral body fat). Visceral fat, which is more metabolically active than subcutaneous fat, has been found to produce many enzymatic signals, e.g. resistin, which increase insulin resistance and circulating VLDL particle concentrations, thus both increasing LDL particle concentrations and accelerating the development of diabetes mellitus.
See also
- Catechin
- Cholesterol
- Lysosomal acid lipase deficiency
- Cholesteryl ester storage disease
- Coenzyme Q10
- Flavonoid
- Glutathione
- Health effects of tea
- High density lipoprotein
- LDL receptor
- Lipid profile
- Lipoprotein(a)
- Lipoprotein-X
- Melatonin
- Polyphenol antioxidant
- Saturated fat
- Stanol ester
- Sterol ester
- Triglyceride
- Vitamin A
- Vitamin C
- Vitamin E
Notes and references
- ^ "LDL and HDL: Bad and Good Cholesterol". Centers for Disease Control and Prevention. CDC. Retrieved 11 September 2017.
- PMID 22355656.
- S2CID 20566238.
- ^ PMID 11518754.
- ISBN 978-981-4998-07-9.
- PMID 31838890.
- PMID 1450174.
- PMID 21573056.
- PMID 30137845, retrieved 2022-12-26
- S2CID 326884.
- PMID 18753623.
- PMID 33655296.
- PMID 19064256.
- ^ "When it comes to LDL, size matters". HLTH Code. 2022-07-18. Retrieved 2022-08-04.
- ^ PMID 28572872.
- PMID 15971461.
- ^ "No association between 'bad cholesterol' and elderly deaths: Systematic review of studies of over 68,000 elderly people also raises questions about the benefits of statin drug treatments". sciencedaily.com.
- PMID 12417832.
- ^ PMID 2297909. Archived from the originalon 2019-09-12. Retrieved 2009-11-02.
- PMID 10376193.
- PMID 9026539.
- ^ S2CID 3397099.
- ^ PMID 15383655.
- S2CID 7852910.
- PMID 19141435.
- ^ John D. Brunzell, MD, FACP, Michael Davidson, MD, FACC, Curt D. Furberg, MD, PhD, Ronald B. Goldberg, MD, Barbara V. Howard, PhD, James H. Stein, MD, FACC, FACP and Joseph L. Witztum, MD Lipoprotein Management in Patients With Cardiometabolic Risk, J Am Coll Cardiol, 2008; 51:1512-1524. [1] Archived 2012-02-27 at the Wayback Machine
- PMID 4337382. Archived from the originalon 2019-09-12. Retrieved 2008-05-05.
- PMID 14563441.
- PMID 15939107.
- S2CID 207193749.
- S2CID 414939.
- PMID 24240933.
- PMID 32101259.
- ^ S2CID 232309411.
- ^ http://www.liposcience.com/userfiles/content/files/weightofevidence.pdf[permanent dead link]
- ^ "Cholesterol Levels". American Heart Association. Retrieved 2009-11-14.
- ^ "What Do My Cholesterol Levels Mean?" (PDF). American Heart Association. September 2007. Retrieved 2009-11-14.
- ^ "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary" (PDF). National Heart, Lung, and Blood Institute (NHLBI). National Institutes of Health. May 2001.
- PMID 7566020.
- PMID 17387127.
- S2CID 29849069.
- ^ "The straight dope on cholesterol – Part VI - The Eating Academy - Peter Attia, M.D." 30 May 2012. Archived from the original on 6 May 2016. Retrieved 24 April 2016.
- S2CID 229942314.
- PMID 32412961.
- PMID 10712410.
- PMID 16306559.
- PMID 24956532.
- S2CID 1775446.
- PMID 18402913.
- ^ "Google". www.google.com.
- ^ "MESA - Multi-Ethnic Study of Atherosclerosis". www.mesa-nhlbi.org.
- ^ "Management of Blood Cholesterol in Adults: Systematic Evidence Review from the Cholesterol Expert Panel | National Heart, Lung, and Blood Institute (NHLBI)". Archived from the original on 2014-11-25. Retrieved 2014-11-16.
- ^ "Archived copy" (PDF). Archived from the original (PDF) on 2016-03-03. Retrieved 2014-11-16.
{{cite web}}
: CS1 maint: archived copy as title (link) - ^ a b c d e f g h Consumer Reports; Drug Effectiveness Review Project (March 2013), "Evaluating statin drugs to treat High Cholesterol and Heart Disease: Comparing Effectiveness, Safety, and Price" (PDF), Best Buy Drugs, Consumer Reports, p. 9, retrieved 27 March 2013, which cites
- United States Department of Health and Human Services; National Heart, Lung, and Blood Institute; National Institutes of Health (June 2005). "NHLBI, High Blood Cholesterol: What You Need to Know". nhlbi.nih.gov. Archived from the original on 2013-04-01. Retrieved 27 March 2013.
{{cite web}}
: CS1 maint: multiple names: authors list (link)
- United States Department of Health and Human Services; National Heart, Lung, and Blood Institute; National Institutes of Health (June 2005). "NHLBI, High Blood Cholesterol: What You Need to Know". nhlbi.nih.gov. Archived from the original on 2013-04-01. Retrieved 27 March 2013.
- ^ Research, Center for Drug Evaluation and. "Drug Safety Information for Healthcare Professionals - Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)". Food and Drug Administration.
- PMID 15529025.
- S2CID 20876888.
- S2CID 2473318.
- ^ http://www.rxabbott.com/pdf/trilipix_pi.pdf [bare URL PDF]
- PMID 16831864.
- ^ European Food Safety Authority, Journal (2010). "Scientific opinion on the substantiation of health claims related to plant sterols and plant stanols and maintenance of normal blood cholesterol concentrations".
- PMID 30205492.
- PMID 29267628.
- PMID 19091798.
- ^ "Scientists Gene-Hacked Monkeys to Fix Their Cholesterol". Futurism. Retrieved 13 June 2021.
- S2CID 234790939. Retrieved 13 June 2021.
- ^ a b "Cholesterol Diet: How Nutrition & Foods Impact Levels". Cleveland Clinic. Retrieved 2024-02-16.
- ^ "Saturated Fat". www.heart.org. Retrieved 2024-02-16.
- ^ Nutrition, Center for Food Safety and Applied (2023-08-30). "Trans Fat". FDA.
- ^ "Trans Fatty Acid - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 2024-02-16.
External links
- Fat (LDL) Degradation: PMAP The Proteolysis Map-animation
- Adult Treatment Panel III Full Report
- ATP III Update 2004
- O'Keefe JH, Cordain L, Harris WH, Moe RM, Vogel R (June 2004). "Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal". Journal of the American College of Cardiology. 43 (11): 2142–6. PMID 15172426.